Canaquest Medical Corporation · OTC:CANQF
Canaquest Medical — Investor Presentation (February 2022)
17 slides from Canaquest Medical's investor presentation, February 2022
Slide 1: Corporate Presentation Q1 2022
Corporate Presentation Q1 2022 Mission | To advance cannabinoid & botanical-based medicine to the forefront by deploying best-practice science, clinical trials, and emerging technologies
Slide 2: Forward Looking Statements
Forward Looking Statements To the extent of statements made in this presentation contains forward looking statements and information that are based upon beliefs of, and information currently available to, the company's management as well as estimates and assumptions made by the company’s management.
Slide 3: Problem – Mental Disorders On The Rise
Problem – Mental Disorders On The Rise | Limited science behind “medical” cannabis products • Global cost - mental disorders will cost the global economy $16 trillion by 2030¹ • Mental health ailments - 1 in 5 North Americans has some type of mental health condition2,3 • Limited science-backed canna
Slide 4: Solution - Game Changing Formulations
Solution - Game Changing Formulations |Medical cannabis products used as formulation bases for Rx drug candidates Mentanine® - CBD based formulation Base formulation for drug candidate Rx CQ-001 • Synergistically attaches to PPAR receptor allowing CBD to cross the blood-brain barrier (BBB) to intera
Slide 5: Value Proposition – Rx Drug Candidates for Pre-approved Trials
Value Proposition – Rx Drug Candidates for Pre-approved Trials |Novel formulation bases, proprietary processing, and delivery formats for Rx drug candidates (1) University of Montreal Hospital Research Centre Ontario Brain Institute • Pre-clinical trials completed – Western University • Pre-approved
Slide 6: Pharmaceutical Comparable - Unique Formulation
Pharmaceutical Comparable - Unique Formulation | Comparison with similar FDA approved product Rx CQ-001 Epidiolex® Double acting formula – on the center nervous system (the Acts on the endocannabinoid system, requiring high dosage to brain) and endocannabinoid system reach desired results at the bra
Slide 7: Mental Health Costs
Mental Health Costs | Significant Mental Health Ailments to be Addressed $16 Trillion Mental Illness Will Cost the World $16 USD Trillion by 2030¹ $225 Billion Mental Health Costs in the US reached $225 USD Billion in 2019 - 5.5% of all health spending2 $50 Billion Mental Illness in Canada is at lea
Slide 8: Pharmaceutical Regulatory Pathway To Market
Pharmaceutical Regulatory Pathway To Market | Patients Suffering from Epilepsy – Dravet & Lennox Gastaut Syndrome, and Tuberous Sclerosis Complex Total Addressable Market ~ 1.1M patients worldwide Serviceable Addressable Market 160,000 patients in US, Canada & EU Serviceable Obtainable Market 80,000
Slide 9: Steps to US-FDA and Health Canada Approvals
Steps to US-FDA and Heath Canada Approvals |Obtaining Drug Identification Numbers DIN for Rx CQ-001 Targeting Rx drug candidate for two epilepsy rare conditions COMPLETED STEPS NEXT STEPS TO OBTAIN A DIN FOR Rx CQ-001 – Mentanine® base formulation CanaQuest Scientific Partnership Network US-FDA Comp
Slide 10: Steps to US-FDA and Health Canada Approvals
Steps to US-FDA and Heath Canada Approvals | Obtaining Drug Identification Numbers DIN for Rx CQ-002 Targeting Rx candidate as a neurological drug COMPLETED STEPS FOR Rx CQ-002 NEXT STEPS TO OBTAIN A DIN FOR Rx CQ-002 – Mentabinol® base formulation CanaQuest Scientific Partnership Network CanaQuest
Slide 11: Partnerships - Manufacturing
Partnerships - Manufacturing | Processing has commenced Canada USA Launching Mentanine® and Mentabinol® - Q1 2022 Launching Mentanine® - Q1 2022 Hydrx Farms, Ontario https://hydrx.ca/facilities/ • GMP compliance with regulatory requirements of Health Atrium Scientific, California www.atriumsci.com C
Slide 12: Partnerships - Distribution
Partnerships - Distribution | Distribution and physician network in place Canada USA Canadian Cannabis Clinics Dr Rick Goulding (MD), Florida - American Medical Association ▪ Established relationships with MediKush, Pathway Health, Mentanine® distribution in the US Canada House, Hybrid Pharm. ▪ 15,0
Slide 13: Executive Team & Board of Directors
Executive Team & Board of Directors | 100+ Years of Management & Product Development Experience Richard Rusiniak, Mechanical Engineer, CEO – Director • Over 35 years of management, design and process experience; • Co-founder and former President, CFO, and CTO of Cymat Corp (TSX: CYM) with a market v
Slide 14: Scientific Partners & Regulatory Advisors
Scientific Partners & Regulatory Advisors Dr. Steven Laviolette, B.Sc., Ph.D., a Professor and Neuroscientist in the Schulich School of Medicine & Dentistry at Western University, Addiction Research Group Dept. of Anatomy & Cell Biology, Dept. of Psychiatry R & D Program - 14 scientists https://www.
Slide 15: Scientific Partners & Pharmaceutical Advisor
Scientific Partners & Pharmaceutical Advisor Dr. David W.L. Ma, Ph.D. Medical Sciences, Professor, Department of Human Health and Nutritional Sciences, University of Guelph R & D Program - 5 scientists https://www.uoguelph.ca/hhns/people/dr-david-wl-ma • Previously, had faculty position in the Depar
Slide 16: CanaQuest Highlights
CanaQuest Highlights | World-leading scientists in neurology, clinical trials and Rx Drug Approvals • Leader - in cannabinoid-based drug development for treating mental health neurological conditions • Clinical trial stage - strong science, pre-clinical trial results and peer-reviewed reputable publ
Slide 17: Thank you
Thank you Contact Information: Paul Ramsay, President 416.704.3040 paul@canaquest.com www.canaquest.com 17
CanaQuest Medical — Investor Presentation (February 2022) on 6ix